Nob Hill Therapeutics Selected for Featured Poster Presentation at Respiratory Innovation Summit

Nob Hill Therapeutics

Albuquerque, NM, May 19, 2023 – Nob Hill Therapeutics (NHT), an inhalation technology company, today announced that it has been selected to be a featured poster presentation at the ATS 2023 Respiratory Innovation Summit (RIS). The RIS will be held in Washington, DC from May 19-20, 2023.

NHT’s poster will highlight the company’s technology platform, which enables high doses of medicine to be delivered to a patient’s lungs. NHT believes this technology could allow new treatment options for several diseases such as lung fungal infections, lung cancer, and cystic fibrosis.

The ATS 2023 RIS is hosted by the American Thoracic Society and will unite innovators, investors, clinicians and advocacy groups who are leading the charge to create new treatments for deadly and crippling diseases of the lungs and airways.

“We are pleased to be a featured poster presentation at the ATS 2023 RIS program,” said Noel Greenberger, CEO of Nob Hill Therapeutics. “This is a special accomplishment for our company and demonstrates our commitment to innovation and pulmonary patient care.”

About Nob Hill Therapeutics

Nob Hills Therapeutics (NHT) is a respiratory-focused healthcare company that uses high dose lung delivery to change the treatment paradigm for lung-related diseases. NHT’s patented Dry Powder Nebulizer platform has several technological innovations that enables it to generate highly efficient drug aerosols and deliver them effectively to the lower respiratory tract, independent of the patient’s lung capacity. To learn more, please visit